Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7062931 SAD in Healthy Chinese Volunteers
NCT03505190Phase 1Completed
- Sponsor
- Roche
- Start
- May 2018
- Primary completion
- Jul 2019
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RO7062931 in Chronic Hepatitis B (CHB) (5 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events and AEs of Special Interest up to 16 weeks, Percentage of Participants With Marked Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation and Urinalysis Test Results at Day 85 and 3 more. Started May 2018; status: completed.
02
Drugs
RO7062931
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03505190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505190.